Momenta Pharmaceuticals
Biotechnology company that pioneered the development of complex biosimilars and novel therapeutics for autoimmune and rare diseases. Acquired by Johnson & Johnson in 2020 for $6.5 billion.
Location
Cambridge, Massachusetts, USA
Founded
2001
Investors
1
Categories
biotech, biosimilars, therapeutics, autoimmune, rare-disease, immunology
Notes
Momenta Pharmaceuticals was a biotechnology company that pioneered the development of complex biosimilars and novel therapeutics for autoimmune and rare diseases. The company developed expertise in characterizing and manufacturing complex molecules, enabling it to create high-quality biosimilars and innovative new drugs.
Founded in 2001, Momenta was acquired by Johnson & Johnson in August 2020 for approximately $6.5 billion, primarily for its novel Fc-engineered antibody technology and lead candidate nipocalimab for autoimmune diseases.
Team
- Craig Wheeler - Former President & CEO (at time of acquisition)
- Company now part of Johnson & Johnson
Additional Research Findings
- Founded in 2001
- Headquarters was in Cambridge, Massachusetts
- Former portfolio company of Polaris Partners
- Acquired by Johnson & Johnson in August 2020 for ~$6.5 billion
- Was listed on NASDAQ (MNTA)
- Pioneered complex biosimilar development
- Lead candidate nipocalimab for autoimmune diseases
- Fc-engineered antibody platform
- Now integrated into J&J's Janssen pharmaceutical division
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |